Skip to main content
OpenTrials
Completed

NCT Number: NCT03300804

Dose Escalation Trial of Traditional Chinese Medicine for Irritable Bowel Syndrome (TCM- IBS)

The purpose of this study is to determine whether a 20- herb formulation, as a well characterised extract, is efficacious in treating irritable bowel syndrome (IBS) and also to identify efficacious and safe dosage of the formulation in treating IBS.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Medical Gastroenterelogy Clinic Of the Prince Of Wales, Chinese University of Hong Kong

Shatin, Hong Kong

About this study

The Specific aims of the project are:

  • To determine whether a 20- herb formulation improves pain/ discomfort and disturbed bowel frequency in patients with Irritable Bowel Syndrome who have been disappointed with current conventional Western medicine.
  • To identify an optimal dosage of the 20- herb formulation that is safe and well tolerated for up to 8 weeks of treatment, among 2 dosages. This is determined by relief of symptoms of IBS in a dose escalation, placebo-controlled double- blind randomized clinical trial, in conjunction with indices of safety and tolerability.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18- 75
  • All IBS patients attending the Gastroenterology Clinic of the Prince Of Wales Hospital of Hong Kong.
  • IBS diagnosed by Rome III criteria:
  • Recurrent abdominal pain or discomfort at least three days per month in the previous three months
  • Symptoms onset at least six months prior to diagnose
  • Pain or discomfort associated with two or more of the following:
  • Improvement with defecation
  • Onset associated with change in frequency of stool
  • Onset associated with a change in form (appearance) of stool
  • Normal colonic evaluation (colonoscopy or barium enema) in past 5 years
  • No "global symptom improvement" as rated by patients (see below) at screening and during the two- week run- in period to baseline
  • Normal full blood count, liver function test and renal function test.
  • Informed written consent for participation into study.
  • Ethical approval will be obtained from the Joint CUHK-NTEC Clinical Research Ethics Committee as well as the IRB of UMB.

Exclusion criteria

  • Past or present history of organic disease of gastrointestinal tract (e.g. colorectal cancer, advanced colonic polyp, celiac disease, inflammatory bowel disease, peptic ulcer and previous gastrointestinal surgery). (Note: those with polyps removed during colonoscopy can be included, as long as no known polyps remained.
  • Systemic diseases that cause diarrhea or constipation (e.g. thyroid disease, diabetic neuropathy)
  • Lactose intolerance
  • Severe liver disease (e.g. cirrhosis, chronic active hepatitis)
  • Renal impairment (serum creatinine level > 150mmol/L)
  • Women who are pregnant, lactating or not practicing proper contraception
  • Known hypersensitivity to herbal medicine
  • Concommitant use of prescription antidepressant medication
  • Current alcoholism and drug use
  • Current psychiatric illness or dementia
  • Fever or severe illness at baseline (week 0).

Treatment and study plan

20-herb formulation

Drug

Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks

Placebo

Drug

Placebo herb formulation

Primary outcomes

  1. Global IBS symptom improvement

    Time frame: 8 weeks

    The primary endpoint for this study is the efficacy at the 8 week followup visit of the herbal formulations, which is defined by the patient's global assessment of the IBS symptoms.

Secondary outcomes

  1. The Bowel Symptom Scale (BSS):

    Time frame: 8 weeks

    The Bowel Symptom Scale will be used to assess changes in individual IBS and global IBS symptoms during the course of illness.

  2. SF-36

    Time frame: 8 weeks

    Quality of Life generic (SF-36), will be used for assessment of quality of life in response to treatment.

  3. IBS-QoL

    Time frame: 8 weeks

    Disease-specific (IBS-QoL) will be used for assessment of quality of life in response to treatment.

Sponsors and collaborators

Lead sponsor

University of Maryland, Baltimore

Other

Collaborators

  • Chinese University of Hong Kong
  • National Center for Complementary and Integrative Health (NCCIH)

Registry information

Official study title

Dose Escalation Trial Of Traditional Chinese Medicine For Irritable Bowel Syndrome

Acronym: TCM-IBS

Important dates

Study start
2008
Primary completion
2011
Study completion
2011
First posted
Oct 4, 2017
Registry last updated
Mar 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.